Bladder Cancer Treatment (PDQ®)–Health Professional Version
SECTIONS
- General Information About Bladder Cancer
- Cellular Classification of Bladder Cancer
- Stage Information for Bladder Cancer
- Treatment Option Overview for Bladder Cancer
- Stage 0 Bladder Cancer Treatment
- Stage I Bladder Cancer Treatment
- Stages II and III Bladder Cancer Treatment
- Stage IV Bladder Cancer Treatment
- Recurrent Bladder Cancer Treatment
- Changes to This Summary (04/12/2018)
- About This PDQ Summary
- View All Sections
Changes to This Summary (04/12/2018)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Pembrolizumab as a new subsection.
Revised the Atezolizumab subsection.
Added Avelumab as a new subsection.
Added Durvalumab as a new subsection.
Added Pembrolizumab as a new subsection.
Revised the Atezolizumab subsection.
Added Avelumab as a new subsection.
Added Durvalumab as a new subsection.
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario